Communiqués Cybin

Actions

HELP

CA23256X4075

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 15:56:44 02/10/2026			Varia. 5j.	Varia. 1 janv.
11,68 ^USD	-1,93%		-5,63%	+45,48%

01/10	Cybin change de dénomination juridique pour devenir Helus Pharma	MT
22/09	Cybin Inc. élit Michael Halstead au poste d’administrateur	CI

Communiqués

01/10	Helus Pharma Announces Completion of Legal Name Change	AQ
22/09	Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change	GL
21/09	Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit	GL
21/09	Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026	GL
10/09	Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New York	GL
09/09	Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York	GL
03/09	Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York	GL
18/08	Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board	GL
14/08	Cybin : MDA Q1 27 FINAL	PU
14/08	Cybin : Financial Statements Q1 27 FINAL	PU
14/08	Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights	GL
10/08	Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston	GL
05/08	A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout	AQ
03/08	Helus Pharma Appoints Michael Halstead as Chief Executive Officer	GL
21/07	Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates	AQ
21/07	Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule	GL
29/06	Cybin : MDA Q4 26 (Exhibit 99.3) Final	PU
29/06	Cybin : Annual Information Form (AIF) March 31 2026 (Exhibit 99.1) Final	PU
29/06	Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results	GL
26/06	Cybin : Financial Statements Q4 26 (Exhibit 99.2) Final	PU
25/06	Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering	GL
24/06	Helus Pharma™ Announces US$50 Million Underwritten Offering	GL
24/06	Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress	GL
11/06	Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference	GL
01/06	Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York	GL